2024-07-23 15:09:01 ET
Summary
- Cellectar Biosciences, Inc. announced that the primary endpoint was met in the pivotal phase 2 CLOVER WaM study, using iopofosine for the treatment of patients with relapsed/refractory Waldenstrom's Macroglobulinemia or WM.
- The NDA submission of ipofosine for relapsed/refractory WM patients is expected in Q4 of 2024. The potential to have therapy given Priority Review.
- The company believes that the possible market for relapsed/refractory WM patients in the United States stands at a $1.05 billion market opportunity.
- An interim assessment and trial results from the phase 1b study using iopofosine for pediatric high-grade glioma are expected 2nd half of 2024 and the second half of 2025, respectively.
Cellectar Biosciences, Inc. ( CLRB ) recently reported positive results from its pivotal phase 2 CLOVER WaM study, using iopofosine for the treatment of patients with refractory Waldenstrom's macroglobulinemia [WM]. The stock traded slightly lower on the news, but only because some efficacy measures dropped slightly since the previous update. However, I believe that such a drop is not warranted at all. Why do I believe this to be the case? That's because the primary endpoint of the major response rate [MRR] was still exceeded by a massive margin, regardless of the slight drop in this metric....
Read the full article on Seeking Alpha
For further details see:
Cellectar: WM Treatment Data Leads To A Few Regulatory Milestones